Regulatory affairs specialist firm to branch out into R&D
Regulatory affairs service provider ELC Group is expanding into the pharma development market.
It will create a product portfolio targeting a range of therapeutic areas, and market them across the USA, European Union, Latin America, Middle East and North Africa, and China. It estimates that the complete portfolio will generate $2 billion in annual sales after initial launch, and the company intends to sign key strategic global partners for licensing and distribution.
The portfolio will cover indications in oncology, cardiovascular, diabetes, pain management and ophthalmic solutions. The products were selected based on global market size, annual drug sales, prior experience and expertise, among other criteria. Some are being developed with specific intellectual property considerations and will qualify as Paragraph IV filings in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze